CN Patent

CN1291994A — 新的(2e)－5－氨基－5－甲基已－2－烯酸n－甲基－n－((1r)－1－(n－甲基－n－(1r)－1－(甲基氨基甲酰基)－2－苯2基氨基甲酰基－2－(2－萘基)2基酰胺的盐

Assigned to Novo Nordisk AS · Expires 2001-04-18 · 25y expired

What this patent protects

本发明涉及(2E)－5－氨基－5－甲基己－2－烯酸N－甲基－N－((1R)－1－(N－甲基－N((1R)－1－(甲基氨基甲酰基)－2－苯乙基)氨基甲酰基)－2－(2－萘基)乙基)酰胺的盐、其制备以及作为治疗剂的用途。

USPTO Abstract

本发明涉及(2E)－5－氨基－5－甲基己－2－烯酸N－甲基－N－((1R)－1－(N－甲基－N((1R)－1－(甲基氨基甲酰基)－2－苯乙基)氨基甲酰基)－2－(2－萘基)乙基)酰胺的盐、其制备以及作为治疗剂的用途。

Drugs covered by this patent

Veklury (remdesivir) · Gilead Sciences

Patent Metadata

Patent number: CN1291994A
Jurisdiction: CN
Classification: —
Expires: 2001-04-18
Drug substance claim: No
Drug product claim: No
Assignee: Novo Nordisk AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.